Magnesium-containing products and uses thereof
AssigneeNaveh Pharma (1996) Ltd.
InventorNITSAN PRIMOR
Life of this patent
Estimating the term…
Abstract
A composition including a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH)2, at a concentration ranging from 0 to 99 wt %; or Mg(OH)2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.
Claims19
A composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2.
A method of treating a subject in need of magnesium supplementation, the method comprising administering to the subject a therapeutically effective amount of a composition selected from the group consisting of:
- A composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2;
- and a pharmaceutical composition comprising a hydrate form of magnesium oxide selected from the group including:
- d. Magnesium oxide hydrate MgO.(H2O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and MgO at a concentration ranging from 0 to 99 wt %;
- or
- e. Magnesium oxide hydrate MgO.(H2O)n, at a concentration ranging from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and Mg(OH)2, at a concentration ranging from 0 to 99 wt %;
- or
- f. Magnesium oxide hydrate MgO.(H2O)n, at a concentration ranging from 1 to 100 wt %, wherein n is any value from 0.1 to 2, and Mg(OH)2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.
A pharmaceutical composition unit dosage form for oral administration, the composition comprising a magnesium salt selected from the group consisting of magnesium oxide hydrate MgO.(H2O)n, wherein n is any value from 0.1 to 2, MgO and Mg(OH)2, the composition being characterized as capable of generating free magnesium ions from at least 50% of its magnesium content under physiological conditions of a human stomach.
A pharmaceutical composition unit dosage form for oral administration, the composition comprising a magnesium salt selected from the group consisting of magnesium oxide hydrate MgO.(H2O)n, wherein n is any value from 0.1 to 2, MgO and Mg(OH)2 and is being characterized as capable of generating free magnesium ions from at least 80% of its magnesium content when dissolved in an acidic aqueous solution for 45 minutes at room temperature.
Dependencies are inferred from the claim text.